Leukemia treatment is a journey that typically unfolds in phases. Understanding these phases—and the various treatment options within them—helps you know what to expect and empowers you to participate in decisions about your care.

📋 Treatment Phases

Most leukemia treatment follows a structured approach with distinct phases. Each phase has specific goals and different intensity levels.

💉 Induction Regimens

The "7+3" Standard

For many years, the standard treatment for Acute Myeloid Leukemia (AML) has been the "7+3" regimen. It is called 7+3 because it involves two types of chemotherapy:

• Cytarabine (Ara-C): Given continuously for 7 days via IV infusion.
• Daunorubicin or Idarubicin: Given as a quick infusion on days 1, 2, and 3.

HMA + Venetoclax

For patients who may not tolerate intensive chemotherapy (often older adults or those with other health conditions), the combination of a Hypomethylating Agent (HMA) and Venetoclax has become a standard of care.

Vyxeos (CPX-351)

CPX-351 (Vyxeos) is a specialized liposomal formulation combining Cytarabine and Daunorubicin in a fixed ratio. It's specifically approved for patients with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes.

🔥 FLAG-IDA Regimen

FLAG-IDA is an intensive chemotherapy regimen often used for relapsed or refractory AML, though sometimes it's used as a frontline option for high-risk patients.

🎯 Targeted Therapy Regimens

If your leukemia has specific genetic mutations, your doctor may add a targeted drug to your regimen. These drugs are designed to attack the unique vulnerabilities in your cancer cells.

🧬 CAR-T Cell Therapy

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a groundbreaking form of immunotherapy that reprograms your own immune cells to fight cancer. Unlike chemotherapy, which broadly attacks dividing cells, CAR-T creates a living drug — your own T-cells are engineered to recognize and destroy cancer cells with precision.

How It Works — Step by Step

1

T-Cell Collection (Leukapheresis)

The process begins with leukapheresis, a procedure similar to a blood donation. Blood is drawn from one arm, passed through a machine called an apheresis device that separates out your white blood cells — specifically T-cells — and returns the remaining blood through the other arm. The session typically takes 3-6 hours.

💡 You'll be awake and comfortable during the procedure. An IV line is placed in each arm.

2

Genetic Engineering

Your collected T-cells are sent to a specialized laboratory. Using a harmless viral vector (a deactivated virus), scientists insert a new gene into the T-cells. This gene codes for the Chimeric Antigen Receptor (CAR) — a synthetic protein that will appear on the surface of the cell and acts like a "homing beacon," allowing the T-cell to recognize a specific target on cancer cells (such as the CD19 protein on B-cell leukemias).

🔬 This engineering happens at specialized manufacturing facilities and is unique to each patient.

3

Cell Expansion

Once engineered, the CAR-T cells are placed in a bioreactor — an incubator-like device that provides the perfect conditions for cells to grow. Over 2-4 weeks, a handful of modified cells multiply into hundreds of millions of cancer-fighting CAR-T cells. Rigorous quality checks ensure the cells are healthy, potent, and safe before they are shipped back to your treatment center.

📦 The finished cells are cryopreserved (frozen) and shipped to your hospital in a special container.

4

Infusion & Cancer Attack

Before infusion, you'll receive a short course of lymphodepleting chemotherapy (usually Fludarabine and Cyclophosphamide for 3 days) to suppress your existing immune cells and create "room" for the CAR-T cells. Then, the CAR-T cells are infused through an IV — similar to a blood transfusion. Once inside your body, the CAR-T cells seek out, bind to, and destroy cancer cells carrying the target protein. They continue to multiply and patrol for cancer long after the infusion.

🏥 You'll be monitored closely in the hospital for at least 7-14 days after infusion.

Current Approvals & Research

CAR-T therapy is currently FDA-approved for certain types of B-cell Acute Lymphoblastic Leukemia (ALL)that has relapsed or not responded to other treatments. Products include:

For AML, CAR-T research is active but still primarily in clinical trials. Promising targets include CD33 and CD123. If your doctor recommends exploring CAR-T, check our Clinical Trials page for guidance.

🏥 Supportive Care & Ancillary Treatments

Beyond the direct anti-leukemia drugs, you'll receive many supportive treatments to help your body through therapy and prevent complications. These are just as important as the chemotherapy itself.

🎗️ Lymphoma Treatment Regimens

Lymphoma treatment varies significantly by subtype. Below are the most important regimen families used across Hodgkin and Non-Hodgkin lymphomas.